Overview of treatment options for invasive fungal infections
| Autor: | Vincent Dimondi, Melanie W. Pound, Richard H. Drew, Mary L. Townsend, Dustin Wilson |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Voriconazole
Drug Posaconazole medicine.medical_specialty Antifungal Agents Echinocandin business.industry media_common.quotation_subject General Medicine Chemoprevention Flucytosine Infectious Diseases Mycoses Amphotericin B deoxycholate Amphotericin B Immunology Humans Medicine business Intensive care medicine Fluconazole medicine.drug media_common |
| Zdroj: | Medical Mycology. :1-20 |
| ISSN: | 1460-2709 1369-3786 |
| Popis: | The introduction of several new antifungals has significantly expanded both prophylaxis and treatment options for invasive fungal infections (IFIs). Relative to amphotericin B deoxycholate, lipid-based formulations of amphotericin B have significantly reduced the incidence of nephrotoxicity, but at a significant increase in drug acquisition cost. Newer, broad-spectrum triazoles (notably voriconazole and posaconazole) have added significantly to both the prevention and treatment of IFIs, most notably Aspergillus spp. (with voriconazole) and the treatment of some emerging fungal pathogens. Finally, a new class of parenteral antifungals, the echinocandins, is employed most frequently against invasive candidal infections. While the role of these newer agents continues to evolve, this review summarizes the activity, safety and clinical applications of agents most commonly employed in the treatment of IFIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|